GKGreta Klejborowska

Greta Klejborowska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Greta Klejborowska has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Oxazole-Based Ferroptosis Inhibitors with Promising Properties to Treat Central Nervous System Diseases

    by Camilla Scarpellini, Greta Klejborowska, Caroline Lanthier, Ariane Toye, Karolina Musiałek, Emily Van San, Magali Walravens, Maya Berg, Behrouz Hassannia, Pieter Van der Veken, et al.

    Ferroptosis plays an important role in the occurrence and development of many diseases, including neurodegenerative diseases. Thus, ferroptosis inhibitors able to cross the blood-brain barrier may have therapeutic potential. The best ferroptosis inhibitors so far are lipophilic radical trapping antioxidants (RTAs) that block lipid peroxidation in membranes. Several generations of ferrostatins have been synthesized, among which UAMC-3203 showed high potency in animal models with improved properties compared to ferrostatin-1. To further improve its pharmacokinetics properties, drug-likeness, and permeability, we modified UAMC-3203 by decreasing the size of the molecule and reducing its polarity by replacing the sulfonamide first by amide groups and subsequently by isosteric oxazoles. Herein, we present the design, synthesis, and biological evaluation of a novel series of oxazole RTAs with high potency, excellent oral bioavailability, and high concentrations in brain tissue.


  • Open Access

    Monensin and its Derivatives Exhibit Anti-Melanoma Activity In Vitro

    by Alicja Urbaniak, Marta Jędrzejczyk, Greta Klejborowska, Natalia Stępczyńska, Adam Huczyński, Alan J. Tackett

    ID 15572 Poster Board 552 Over the last 30 years, incidences of melanoma have increased dramatically. Although, melanoma accounts only for approximately one percent of skin cancers, it is responsible for almost eighty percent of all deaths from dermatological malignancies. Current therapeutic approaches vary depending on tumor progression and patient’s health, and include tumor removal, immunotherapy, and forms of targeted therapy. Major limitations in treating melanoma are associated with adverse side effects of treatments as well as reduced drug efficiency. Therefore, new forms of therapy are needed to overcome these limitations as well as to combat the increased incidence of melanoma. Monensin (MON) is a naturally occurring polyether ionophore which was shown to be potent and selective towards different types of cancer cells including melanoma. In order to further explore structure-activity relationship of MON and develop more potent and selective compounds based on the scaffold of MON, we synthesized an extensive library of esters and urethanes, as well as ester-carbonates, amide carbonates, tertiary amides, and esters on the C1 atom. We have identified four derivatives more potent (IC50 = 28.3 ± 6.0 – 132.2 ± 24.4 nM) than parent MON (IC50 = 316.8 ± 25.7 nM) towards human melanoma A375 cell line, four derivatives more active (IC50 = 132.2 ± 50.4 - 442.9 ± 64.8 nM) than MON (IC50 = 794.1 ± 161.9 nM) against human melanoma SK-MEL-5 cell line, while parent MON remained to be the most potent (IC50 = 63.2 ± 30.9 nM) towards mouse melanoma B16F10 cell line. Further studies revealed that these compounds significantly reduced A375 cell migration (23% vs 41% and 35% wound surface area after 53 hours control vs treatment respectively), increased Major Histocompatibility Complex-I and II presentation and Programmed Death - Ligand 1 expression in SK-MEL-5 cell line. Studies are ongoing to explore mechanism behind the activity of these promising novel drug candidates. This work was supported by grants from the National Institutes of Health: P20GM121293 (to AJT), R24GM137786 (to AJT), and R01CA236209 (to AJT), a Barton Pilot Grant from UAMS College of Medicine (to AU), Equipment Award Program from UAMS College of Medicine (to AU).

  • Open Access

    Effect of erythrophagocytosis-induced ferroptosis during angiogenesis in atherosclerotic plaques

    by Pauline Puylaert, Lynn Roth, Melissa Van Praet, Isabel Pintelon, Catalina Dumitrascu, Alexander van Nuijs, Greta Klejborowska, Pieter-Jan Guns, Tom Vanden Berghe, Koen Augustyns, et al.

    Intraplaque (IP) angiogenesis is a key feature of advanced atherosclerotic plaques. Because IP vessels are fragile and leaky, erythrocytes are released and phagocytosed by macrophages (erythrophagocytosis), which leads to high intracellular iron content, lipid peroxidation and cell death. In vitro experiments showed that erythrophagocytosis by macrophages induced non-canonical ferroptosis, an emerging type of regulated necrosis that may contribute to plaque destabilization. Erythrophagocytosis-induced ferroptosis was accompanied by increased expression of heme-oxygenase 1 and ferritin, and could be blocked by co-treatment with third generation ferroptosis inhibitor UAMC-3203. Both heme-oxygenase 1 and ferritin were also expressed in erythrocyte-rich regions of carotid plaques from ApoE−/−Fbn1C1039G+/− mice, a model of advanced atherosclerosis with IP angiogenesis. The effect of UAMC-3203 (12.35 mg/kg/day) on atherosclerosis was evaluated in ApoE−/−Fbn1C1039G+/− mice fed a western-type diet (WD) for 12 weeks (n = 13 mice/group) or 20 weeks (n = 16–21 mice/group) to distinguish between plaques without and with established IP angiogenesis, respectively. A significant decrease in carotid plaque thickness was observed after 20 weeks WD (87 ± 19 μm vs. 166 ± 20 μm, p = 0.006), particularly in plaques with confirmed IP angiogenesis or hemorrhage (108 ± 35 μm vs. 322 ± 40 μm, p = 0.004). This effect was accompanied by decreased IP heme-oxygenase 1 and ferritin expression. UAMC-3203 did not affect carotid plaques after 12 weeks WD or plaques in the aorta, which typically do not develop IP angiogenesis. Altogether, erythrophagocytosis-induced ferroptosis during IP angiogenesis leads to larger atherosclerotic plaques, an effect that can be prevented by ferroptosis inhibitor UAMC-3203.


  • Open Access

    The Potential Role of Regulated Cell Death in Dry Eye Diseases and Ocular Surface Dysfunction

    by Camilla Scarpellini, Alba Ramos Llorca, Caroline Lanthier, Greta Klejborowska, Koen Augustyns

    The research on new treatments for dry eye diseases (DED) has exponentially grown over the past decades. The increased prevalence of dry eye conditions, particularly in the younger population, has received much attention. Therefore, it is of utmost importance to identify novel therapeutical targets. Regulated cell death (RCD) is an essential process to control the biological homeostasis of tissues and organisms. The identification of different mechanisms of RCD stimulated the research on their involvement in different human pathologies. Whereas apoptosis has been widely studied in DED and included in the DED vicious cycle, the role of RCD still needs to be completely elucidated. In this review, we will explore the potential roles of different types of RCD in DED and ocular surface dysfunction. Starting from the evidence of oxidative stress and inflammation in dry eye pathology, we will analyse the potential therapeutic applications of the following principal RCD mechanisms: ferroptosis, necroptosis, and pyroptosis.


  • Synthesis, anticancer activity and molecular docking studies of N-deacetylthiocolchicine and 4-iodo-N-deacetylthiocolchicine derivatives

    by Greta Klejborowska, Alicja Urbaniak, Ewa Maj, Joanna Wietrzyk, Mahshad Moshari, Jordane Preto, Jack A. Tuszynski, Timothy C. Chambers, Adam Huczyński


  • Open Access

    Novel thiocolchicine–vitamin B conjugate for tumor-targeting drug delivery

    by Greta Klejborowska, Lei Chen, Adam Huczynski, Iwao Ojima

  • Open Access

    Synthesis, biological evaluation and molecular docking studies of new amides of 4-bromothiocolchicine as anticancer agents

    by Greta Klejborowska, Alicja Urbaniak, Jordane Preto, Ewa Maj, Mahshad Moshari, Joanna Wietrzyk, Jack A. Tuszynski, Timothy C. Chambers, Adam Huczyński


  • Synthesis, antiproliferative activity, and molecular docking studies of 4‐chlorothiocolchicine analogues

    by Greta Klejborowska, Mahshad Moshari, Ewa Maj, Urszula Majcher, Jordane Preto, Joanna Wietrzyk, Jack A. Tuszynski, Adam Huczyński

    Colchicine is a therapeutic agent currently used in therapies of many diseases. It also shows antimitotic effects and its high cytotoxic activity against different cancer cell lines has been demonstrated many times. To overcome the limitations of colchicine use in anticancer therapy, we synthesized a series of novel triple‐modified 4‐chloro‐7‐carbamatethiocolchicines. All the synthesized compounds have been tested in vitro to evaluate their cytotoxicity towards A549, MCF‐7, LoVo, LoVo/DX and BALB/3T3 cell lines. Additionally, their mode of binding to ß‐tubulin was evaluated in silico. The majority of triple‐modified colchicine derivatives exhibited significantly higher cytotoxicity than colchicine, doxorubicin and cisplatin against tested cancerous cell lines with much higher selectivity index values for four of them.


  • Antiproliferative activity of ester derivatives of monensin A at the C‐1 and C‐26 positions

    by Greta Klejborowska, Marta Jędrzejczyk, Natalia Stępczyńska, Ewa Maj, Joanna Wietrzyk, Adam Huczyński

    Monensin A (MON) is a polyether ionophore antibiotic, which shows a wide spectrum of biological activity, including anticancer activity. A series of structurally diverse monensin esters including its C‐1 esters (1–9), C‐26‐O‐acetylated derivatives (10–15), and lactone (16) was synthesized and for the first time evaluated for their antiproliferative activity against four human cancer cell lines with different drug‐sensitivity level. All of the MON derivatives exhibited in vitro antiproliferative activity against cancer cells at micromolar concentrations. The majority of the compounds was able to overcome the drug resistance of LoVo/DX and MES‐SA/DX5 cell lines. The most active compounds proved to be MON C‐26‐O‐acetylated derivatives (10–15) which exhibited very good resistance index and high selectivity index.


  • Open Access

    Carbamate Derivatives of Colchicine Show Potent Activity toward Primary Acute Lymphoblastic Leukemia and Primary Breast Cancer Cells: In Vitro and Ex Vivo Study

    by Alicja Urbaniak, Fariba Jousheghany, Youzhong Yuan, Segio Pina‐Oviedo, Magdalena Delgado, Urszula Majcher, Greta Klejborowska, Adam Huczyński, Behjatolah Monzavi‐Karbassi, Thomas Kieber‐Emmons, et al.

    Colchicine ( COL ) is the major alkaloid isolated from the plant Colchicum autumnale . It shows strong therapeutic effects towards various types of cancer. Its biological activity is related to its ability to bind to tubulin causing microtubule depolymerization, mitotic arrest, and cell death. The colchicine binding site is an attractive target for potential tubulin polymerization destabilizers. Indeed, a large number of molecules interacting with the colchicine binding site have been designed and synthesized with significant structural diversity. The identification of new therapeutics based on COL structure is warranted due to the toxicity of COL towards normal cells. In order to increase potency and reduce toxicity against normal cells, while retaining the activities in the nanomolar range, a library of novel COL analogs, namely N ‐carbamates of N ‐deacetyl‐4‐(bromo/chloro/iodo)thiocolchicine, has been synthesized (Fig. 1). COL and several of the derivatives arrested MCF‐7 cells in mitosis, and caused microtubule depolymerization. Compounds were then tested against two types of primary cancer cells; adult acute lymphoblastic leukemia (ALL) cells, and human breast cancer (BC) cells derived from newly excised human tumor tissue. These represent more clinically relevant drug screening models compared to established cell lines. Four novel colchicine derivatives showed higher activity towards primary ALL cells (IC 50 = 1.1 ± 0.5 to 6.4 ± 1.4 nM) and nine were more potent towards primary BC cells (IC 50 = 2.3 ± 0.0 to 10.3 ± 4.6 nM) compared to COL (IC 50 = 8.6 ± 0.2 nM and 11.7 ± 3.1 nM, respectively) in cell viability assays. COL and two of the most active derivatives were also shown to be effective in killing BC cells when tested ex vivo using fresh human breast tumor explants derived from residual invasive ductal carcinoma and invasive mucinous carcinoma. The present findings indicate that the COL derivatives described here constitute promising lead compounds for targeting acute lymphoblastic leukemia and different subtypes of breast cancer. Support or Funding Information The present study was funded by a grant (to TCC) from the Arkansas Breast Cancer Research Program. Financial support by grant (to AH. UM, GK) of the Polish National Science Centre (NCN) – No. 2016/21/B/ST5/00111 is gratefully acknowledged . This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .